Earnings Call · Q2 FY2026·2026-08-06

Q2 26EPS 0.00%·Rev n/aQ1 26EPS +10.00%·Rev n/aQ4 25EPS +16.16%·Rev n/aQ3 25EPS +6.12%·Rev n/a⚠ consensus missing

Intellia Therapeutics, Inc. NTLA

Chloe — Conference Operator

Jason Fredette — Vice President of Investor Relations and Corporate Communications

John Leonard — Chief Executive Officer

Ed Dulac — Chief Financial Officer

+2.5%1d on move date3d+9.6%5d+10.2%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NTLA calls or request research access.

More NTLA calls Browse calls Request research access